PUBLISHER: Grand View Research | PRODUCT CODE: 1790428
PUBLISHER: Grand View Research | PRODUCT CODE: 1790428
The U.S. clinical decision support systems market size was valued at USD 2.14 billion in 2024 and is projected to reach USD 3.40 billion by 2030, growing at a CAGR of 8.17% from 2025 to 2030. The widespread adoption of Electronic Health Records (EHRs) across U.S. hospitals and office-based physicians is significantly driving the market growth. According to Simbo AI, as of 2021, approximately 88% of office-based physicians in the U.S. had implemented an Electronic Health Record (EHR) system, more than doubling the adoption rate from just 42% in previous years, has paved the way for seamless integration of CDSS tools that offer real-time alerts, treatment recommendations, and drug interaction checks at the point of care. Moreover, strong policy support through initiatives like the HITECH Act, Meaningful Use incentives, certification programs from HHS, and provisions in the 21st Century Cures Act created a regulatory environment that incentivizes CDSS adoption and ensures interoperability while encouraging innovation.
To learn more about this report, request a free sample copy
Artificial intelligence (AI) and machine learning (ML) technologies are revolutionizing the clinical decision support systems (CDSS) market by providing enhanced features like predictive analytics, pattern recognition, and personalized recommendations. AI-powered CDSS processes large volumes of data, identifies trends, forecasts outcomes, and recommends the best treatment options. For instance, in December 2022, researchers at the University of Texas at Austin's Dell Medical School developed an AI-based CDSS designed to help clinicians engage patients in conversations about nutrition and support decision-making regarding dietary improvements.
Personalized medicine is on the rise, with CDSSs playing a key role. To create customized treatment plans, these systems evaluate patient information, such as genetic data and medical histories. By delivering personalized recommendations, CDSSs improve treatment outcomes and minimize the chances of adverse effects, contributing to the market's growth.
The COVID-19 pandemic has significantly driven the growth of the U.S. clinical decision support systems market, driving wider adoption of these tools. CDSSs were crucial in supporting patient care and resource management by aiding real-time clinical diagnosis and triage of COVID-19 cases. The expansion of online healthcare services across the country further accelerated this trend. Market leaders introduced specialized CDSS solutions for managing COVID-19 data and insights; for instance, in May 2022, Epocrates launched an advanced tool focused on long-term COVID, incorporating the latest clinical guidelines. This increased adoption has been a key factor in market growth during the pandemic.
U.S. Clinical Decision Support Systems Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. clinical decision support systems market report based on product, application, delivery mode, and component: